Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -55.66% is 11% below its 3-year average of -50.07%, around the middle of its 3-year range (-129.17%–-13.04%).
107.73% below its 12-month average of -26.79%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.12%.
RETURN ON ASSETS (ROA)
-55.66%
RETURN ON ASSETS (ROA) AVG TTM
-26.79%
RETURN ON ASSETS (ROA) AVG 3Y
-50.07%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-107.73%
CURRENT VS 3Y AVG
-11.16%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-72.51%
vs the sector median at left
Upstream Bio, Inc.
Market Cap
$249.79M
Return on Assets (ROA)
-55.66%
TTM Avg
-26.79%
3Y Avg
-50.07%
5Y Avg
N/A
Market Cap
$248.50M
Return on Assets (ROA)
-114.79%
TTM Avg
-67.19%
3Y Avg
-63.94%
5Y Avg
-45.91%
Market Cap
$247.62M
Return on Assets (ROA)
-187.80%
TTM Avg
-213.40%
3Y Avg
-188.65%
5Y Avg
-151.14%
Market Cap
$247.27M
Return on Assets (ROA)
-30.39%
TTM Avg
-25.00%
3Y Avg
-35.54%
5Y Avg
-31.17%
Market Cap
$255.88M
Return on Assets (ROA)
-2.06%
TTM Avg
-16.77%
3Y Avg
-17.09%
5Y Avg
-12.28%
Market Cap
$256.47M
Return on Assets (ROA)
-29.15%
TTM Avg
-33.84%
3Y Avg
-33.85%
5Y Avg
-31.54%
Market Cap
$241.94M
Return on Assets (ROA)
N/A
TTM Avg
-14.72%
3Y Avg
-16.00%
5Y Avg
-18.82%
Market Cap
$241.39M
Return on Assets (ROA)
29.16%
TTM Avg
-1.71%
3Y Avg
-34.07%
5Y Avg
-33.80%
Market Cap
$241.34M
Return on Assets (ROA)
-50.89%
TTM Avg
-41.00%
3Y Avg
-37.00%
5Y Avg
-42.85%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $249.79M | -55.66% | -26.79% | -50.07% | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | -114.79% | -67.19% | -63.94% | -45.91% |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | -187.80% | -213.40% | -188.65% | -151.14% |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | -30.39% | -25.00% | -35.54% | -31.17% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -2.06% | -16.77% | -17.09% | -12.28% |
| AC Immune S.A. (ACIU)vs › | $256.47M | -29.15% | -33.84% | -33.85% | -31.54% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | -14.72% | -16.00% | -18.82% |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 29.16% | -1.71% | -34.07% | -33.80% |
| Quantum-Si incorporated (QSI)vs › | $241.34M | -50.89% | -41.00% | -37.00% | -42.85% |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -25.09% | -72.59% | -80.80% | -146.30% |
ROA
-55.7%
ROE
-57.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -40.55% |
| 2024-12-31 | -13.04% |
| 2023-12-31 | -17.52% |
| 2022-12-31 | -129.17% |
